News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
497,408 Results
Type
Article (9951)
Company Profile (158)
Press Release (487202)
Multimedia
Podcasts (18)
Webinars (7)
Section
Business (171247)
Career Advice (366)
Deals (26340)
Drug Delivery (15)
Drug Development (54222)
Employer Resources (22)
FDA (9930)
Job Trends (8946)
News (243999)
Policy (18347)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (5)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (592)
Accelerated approval (24)
ADA (21)
Adcomms (1)
Allergies (100)
Alliances (34409)
ALS (109)
Alzheimer's disease (1009)
Antibody-drug conjugate (ADC) (298)
Approvals (10532)
Artificial intelligence (356)
ASCO (166)
Autoimmune disease (215)
Automation (32)
Bankruptcy (269)
Best Places to Work (7140)
BIO (41)
Biologics (2)
BIOSECURE Act (3)
Biosimilars (127)
BioSpace Insights (27)
Biotechnology (99)
Bladder cancer (141)
Brain cancer (34)
Breast cancer (519)
Cancer (3809)
Cardiovascular disease (226)
Career advice (296)
Career pathing (2)
CAR-T (186)
CDC (2)
Celiac Disease (1)
Cell therapy (522)
Cervical cancer (38)
Clinical research (48844)
Collaboration (1369)
Commercialization (3)
Company closure (4)
Compensation (1484)
Complete response letters (35)
COVID-19 (890)
CRISPR (69)
C-suite (828)
Cystic fibrosis (90)
Data (5802)
Denatured (10)
Depression (110)
Dermatology (62)
Diabetes (358)
Diagnostics (4326)
Digital health (39)
Diversity (2)
Diversity, equity & inclusion (4)
Drug discovery (186)
Drug pricing (16)
Drug shortages (2)
Duchenne muscular dystrophy (186)
Earnings (74363)
Editorial (6)
Employer branding (3)
Employer resources (20)
Events (89241)
Executive appointments (756)
FDA (12599)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (1051)
Gene editing (142)
Generative AI (12)
Gene therapy (359)
GLP-1 (347)
Government (1062)
Grass and pollen (2)
Guidances (285)
Healthcare (9534)
Hematology (95)
HIV (54)
Huntington's disease (24)
IgA nephropathy (66)
Immunology and inflammation (134)
Immuno-oncology (69)
Indications (158)
Infectious disease (1095)
Inflammatory bowel disease (135)
Inflation Reduction Act (8)
Influenza (89)
Intellectual property (263)
Interviews (47)
IPO (12590)
IRA (7)
Job creations (2139)
Job search strategy (281)
JPM (5)
Kidney cancer (20)
Labor market (12)
Layoffs (106)
Leadership (3)
Legal (5293)
Licensing (8)
Liver cancer (48)
Longevity (20)
Lung cancer (526)
Lymphoma (257)
Machine learning (30)
Management (7)
Manufacturing (575)
Marketing (8)
MASH (122)
Medical device (8744)
Medtech (8889)
Mergers & acquisitions (14800)
Metabolic disorders (754)
mRNA (66)
Multiple sclerosis (106)
NASH (4)
Neurodegenerative disease (240)
Neuropsychiatric disorders (49)
Neuroscience (1926)
NextGen: Class of 2026 (3342)
Non-profit (961)
Now hiring (15)
Obesity (249)
Opinion (30)
Ovarian cancer (161)
Pain (178)
Pancreatic cancer (212)
Parkinson's disease (211)
Partnered (15)
Patents (489)
Patient recruitment (523)
Peanut (32)
People (42890)
Pharmaceutical (31)
Pharmacy benefit managers (8)
Phase 1 (15916)
Phase 2 (21882)
Phase 3 (14747)
Pipeline (7525)
Policy (33)
Postmarket research (1581)
Preclinical (6734)
Press Release (34)
Prostate cancer (191)
Psychedelics (12)
Radiopharmaceuticals (199)
Rare diseases (621)
Real estate (3257)
Recruiting (10)
Regulatory (15210)
Reports (25)
Research institute (684)
Resumes & cover letters (53)
Rett syndrome (41)
RNA editing (8)
RSV (51)
Schizophrenia (110)
Series A (192)
Series B (139)
Service/supplier (5)
Sickle cell disease (65)
Special edition (3)
Spinal muscular atrophy (89)
Sponsored (6)
Startups (2289)
Stomach cancer (5)
Supply chain (52)
Tariffs (2)
The Weekly (8)
Vaccines (365)
Venture capital (37)
Weight loss (95)
Women's health (83)
Worklife (1)
Date
Today (9)
Last 7 days (209)
Last 30 days (1598)
Last 365 days (19766)
2026 (12784)
2025 (20000)
2024 (23634)
2023 (27242)
2022 (35531)
2021 (38232)
2020 (34507)
2019 (24030)
2018 (18175)
2017 (19377)
2016 (18545)
2015 (24834)
2014 (22076)
2013 (18600)
2012 (20697)
2011 (20858)
2010 (20702)
Location
Africa (251)
Alabama (76)
Alaska (2)
Arizona (309)
Arkansas (11)
Asia (19035)
Australia (2290)
California (12294)
Canada (3199)
China (587)
Colorado (491)
Connecticut (417)
Delaware (212)
Europe (27299)
Florida (1803)
Georgia (381)
Hawaii (4)
Idaho (47)
Illinois (723)
India (55)
Indiana (323)
Iowa (15)
Japan (407)
Kansas (111)
Kentucky (31)
Louisiana (29)
Maine (26)
Maryland (1221)
Massachusetts (8062)
Michigan (312)
Minnesota (572)
Mississippi (5)
Missouri (85)
Montana (20)
Nebraska (11)
Nevada (117)
New Hampshire (63)
New Jersey (2669)
New Mexico (12)
New York (2845)
North Carolina (1297)
North Dakota (4)
Northern California (6182)
Ohio (292)
Oklahoma (15)
Oregon (21)
Pennsylvania (2268)
Puerto Rico (21)
Rhode Island (31)
South America (424)
South Carolina (76)
South Dakota (1)
Southern California (5064)
Tennessee (126)
Texas (1985)
United States (39722)
Utah (364)
Vermont (1)
Virginia (160)
Washington D.C. (41)
Washington State (983)
West Virginia (2)
Wisconsin (85)
Wyoming (1)
497,408 Results for "bridgene biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Takeda Pumps $770M Into Another BridGene Pact to Hit ‘Undruggable’ Targets
BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket agreements with Keros Therapeutics, AC Immune and Degron Therapeutics in the past nine months.
February 25, 2025
·
2 min read
·
Tristan Manalac
Drug Development
BridGene Biosciences Announces Dosing of First Patient in Phase 1 Study Evaluating Novel TEAD Inhibitor BGC515 in Advanced Solid Tumors
BridGene Biosciences, Inc., a leader in developing covalent small molecule drugs for traditional “hard-to-drug” targets, announced today that the first patient has been dosed in its Phase 1 clinical trial of BGC515, a novel TEAD inhibitor discovered through BridGene’s cutting-edge chemoproteomic platform, IMTAC™.
June 28, 2024
·
3 min read
Drug Development
BridGene Biosciences Achieves the Second Preclinical Milestone in Takeda Collaboration
BridGene Biosciences, Inc. announced a significant preclinical milestone in its collaboration with Takeda.
August 28, 2023
·
3 min read
Business
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates.
January 3, 2024
·
5 min read
Press Releases
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
August 4, 2026
·
14 min read
Mergers & acquisitions
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
The star of the takeover is Forte Biosciences’ investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.
July 27, 2026
·
2 min read
·
Tristan Manalac
Business
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets
BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditional “hard-to-drug” targets, announced today a strategic collaboration and licensing agreement with Galapagos NV (Euronext & NASDAQ: GLPG).
January 3, 2024
·
3 min read
Business
BridGene Biosciences Achieves Milestone in Takeda Collaboration
BridGene Biosciences, Inc. announced that it has achieved a significant milestone in its collaboration with Takeda.
March 8, 2023
·
2 min read
Press Releases
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
August 6, 2026
·
10 min read
Biotech Bay
BridGene Biosciences to Present at Hippo Pathway Targeted Drug Development Summit
BridGene Biosciences, Inc. announced that Wolf Wiedemeyer , Ph.D., head of biology at BridGene, will be giving a presentation, titled “A Covalent TEAD Inhibitor with Exceptional Anti-cancer Activity & Combination Potential,” at the 2nd Annual Hippo Pathway Targeted Drug Development Summit on May 24 in Boston.
May 18, 2023
·
2 min read
1 of 49,741
Next
